论文部分内容阅读
目的:评价尿多酸肽注射液对135例晚期癌症患者生活质量的影响及临床应用价值。方法:应用欧洲癌症研究与治疗组织推出的生活质量核心量表EORTCQLQ-C30(V3.0)中文版,采用多中心、开放、非随机的方法,对135例晚期癌症患者使用尿多酸肽单药治疗,在治疗前后2,4,6周分别进行1次问卷调查;尿多酸肽注射液深静脉点滴给药,1次/d,连续用药4～8周。结果:尿多酸肽对135例晚期癌症患者EORTCQLQ-C30(V3.0)15项领域中位有效改善率为44.5%;其中原发性肝癌、非小细胞肺癌、结直肠癌、乳腺癌、胃癌、食管癌、脑胶质瘤等的15项领域中位有效改善率分别为52.9%,37.0%,42.9%,50.0%,35.8%,37.5%,33.3%。结论:尿多酸肽可明显改善晚期癌症患者的生活质量,在肿瘤临床治疗中具有一定的应用价值。
Objective: To evaluate the effect and clinical value of uroacitin injection on the quality of life in 135 patients with advanced cancer. Methods: A multicenter, open and non-randomized Chinese version of Core Quality of Life Scale EORTCQLQ-C30 (V3.0) was introduced by European Organization for Research and Treatment of Cancer. 135 patients with advanced cancer were treated with UUTPL Drug treatment, respectively, before and after treatment 1, 2, 4, 6 weeks were a questionnaire; uric acid peptide injection deep intravenous drip, 1 / d, continuous medication for 4 to 8 weeks. Results: The median effective rate of urinary polygopeptide in 15 areas of EORTCQLQ-C30 (V3.0) in 135 patients with advanced cancer was 44.5%. Among them, primary liver cancer, non-small cell lung cancer, colorectal cancer, breast cancer, The median effective rates of 15 areas of gastric cancer, esophageal cancer and glioma were 52.9%, 37.0%, 42.9%, 50.0%, 35.8%, 37.5% and 33.3%, respectively. Conclusion: Uroacitides can significantly improve the quality of life of patients with advanced cancer and have certain value in the clinical treatment of cancer.